E-Book, Englisch, 693 Seiten
Tumor Models in Cancer Research
2. Auflage 2010
ISBN: 978-1-60761-968-0
Verlag: Humana Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
E-Book, Englisch, 693 Seiten
ISBN: 978-1-60761-968-0
Verlag: Humana Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Autoren/Hrsg.
Weitere Infos & Material
1;Tumor Models in Cancer Research;3
1.1;Preface;5
1.2;Contents;7
1.3;Contributors;11
1.4;Part I Introduction;15
1.4.1;Chapter 1: Perspectives on the History and Evolution of Tumor Models;16
1.4.1.1;1.1 Introduction and Statement of the Problem;16
1.4.1.2;1.2 Tumor Models for Cancer Drug Development: Where We Were;18
1.4.1.2.1;1.2.1 Historical Basis;18
1.4.1.2.2;1.2.2 Early Screening Models;19
1.4.1.3;1.3 Novel Screens Beget Novel In Vivo Model Challenges;21
1.4.1.3.1;1.3.1 Non-mammalian Models;21
1.4.1.3.1.1;1.3.1.1 Unicellular;21
1.4.1.3.1.2;1.3.1.2 Multicellular;22
1.4.1.3.2;1.3.2 Technology-Intensive Screening;24
1.4.1.3.2.1;1.3.2.1 High-Throughput Screening;24
1.4.1.3.2.2;1.3.2.2 Chemogenomics;25
1.4.1.3.2.3;1.3.2.3 Proteome and Kinome Screens;25
1.4.1.3.2.4;1.3.2.4 Nanotechnology;25
1.4.1.3.2.5;1.3.2.5 RNA Interference;26
1.4.1.3.3;1.3.3 In Vitro Models;26
1.4.1.4;1.4 Tumor Models for Cancer Drug Development: Where We Need to Be;27
1.4.1.4.1;1.4.1 “In Vitro” Area Under the Concentration × Time Curve for Target Effect;28
1.4.1.4.2;1.4.2 Qualification of Compound for In Vivo Study;28
1.4.1.4.3;1.4.3 Initial Rodent Pharmacology and Model Selection;29
1.4.1.4.4;1.4.4 Sample Size and Randomization of Animals;29
1.4.1.4.5;1.4.5 Correlative Studies;29
1.4.1.4.6;1.4.6 Additional Desirable Studies;29
1.4.1.5;1.5 Conclusion;30
1.4.1.6;References;31
1.5;Part II Transplantable Syngeneic Rodent Tumors;34
1.5.1;Chapter 2: Murine L1210 and P388 Leukemias;35
1.5.1.1;2.1 Introduction;36
1.5.1.2;2.2 Role in Drug Screening;36
1.5.1.3;2.3 Characteristics;37
1.5.1.4;2.4 Sensitivity to Clinical Agents;38
1.5.1.5;2.5 Predictive Value;44
1.5.1.6;2.6 Drug-Resistant Leukemias;46
1.5.1.6.1;2.6.1 Resistance to Alkylating Agents;46
1.5.1.6.2;2.6.2 Resistance to Antimetabolites;48
1.5.1.6.3;2.6.3 Resistance to DNA- and Tubulin-Binding Agents;48
1.5.1.7;2.7 Conclusions;50
1.5.1.8;References;52
1.5.2;Chapter 3: Transplantable Syngeneic Rodent Tumors: Solid Tumors in Mice;54
1.5.2.1;3.1 Introduction;55
1.5.2.2;3.2 Compatibility! Compatibility! Compatibility!;55
1.5.2.3;3.3 Compatible But Not Perfect: Inbred Mice and Genetic Drift;55
1.5.2.4;3.4 Evidence of Tumor–Host Incompatibility and Consequences;56
1.5.2.4.1;3.4.1 No-Takes;56
1.5.2.4.2;3.4.2 Spontaneous Regressions or Tumors that Fail to Progress to Over 1,000-mg Size;58
1.5.2.4.3;3.4.3 Excessive Curability;58
1.5.2.4.4;3.4.4 Lack of Invasion and Metastasis;61
1.5.2.5;3.5 Compatibility Problems Unique to Human Tumors in Immune-deficient Mice;61
1.5.2.6;3.6 Passage of Tumors in Cell Culture: Maintaining Genotype, Histology, Biologic Behavior, and Drug–Response Characteristic;62
1.5.2.7;3.7 Cancer: a Cellular Disease, Take-Rate, Feeder Effect, Implications for Cure;63
1.5.2.8;3.8 Results Tabulation of Chemotherapy Trials: Desired Information from a Tumor Model;72
1.5.2.9;3.9 Characterization of a Tumor Model and Quality-Control Monitoring;80
1.5.2.10;3.10 Summary;81
1.5.2.11;3.11 Methods;82
1.5.2.11.1;3.11.1 Tumor Maintenance;82
1.5.2.11.2;3.11.2 Origins of Mouse Tumors Used or Discussed;82
1.5.2.11.3;3.11.3 Chemotherapy of Leukemias: L1210/0;83
1.5.2.11.4;3.11.4 X-Irradiation of Solid Tumors;83
1.5.2.11.5;3.11.5 Chemotherapy of Solid Tumors;83
1.5.2.11.6;3.11.6 End Points Assessing Antitumor Activity Solid Tumors;84
1.5.2.11.6.1;3.11.6.1 Tumor-Growth Delay (T–C Value);84
1.5.2.11.6.2;3.11.6.2 Percent Increase Life Span;84
1.5.2.11.7;3.11.7 Calculation Tumor-Cell-Kill;84
1.5.2.11.8;3.11.8 Activity Rating Solid Tumors;85
1.5.2.11.8.1;3.11.8.1 Activity Rating for Leukemia L1210/0;85
1.5.2.11.9;3.11.9 Non-quantitative Determination Antitumor Activity Tumor-Growth Inhibition (T/C Value);86
1.5.2.12;References;86
1.5.3;Chapter 4: B16 Murine Melanoma: Historical Perspective on the Development of a Solid Tumor Model;90
1.5.3.1;4.1 Introduction;90
1.5.3.2;4.2 Historical Context;91
1.5.3.3;4.3 B16 Melanoma;95
1.5.3.4;4.4 Conclusions;101
1.5.3.5;4.5 Dedication;105
1.5.3.6;References;105
1.6;Part III Human Tumor Xenografts;107
1.6.1;Chapter 5: Human Tumor Xenograft Efficacy Models;108
1.6.1.1;5.1 Introduction;108
1.6.1.2;5.2 Xenograft Tumor Models for Efficacy Evaluation;111
1.6.1.2.1;5.2.1 Immunodeficient Mice;111
1.6.1.2.2;5.2.2 Cultured Tumor Cells Vs. Tumor Fragments;112
1.6.1.2.3;5.2.3 Subcutaneous Vs. Orthotopic Transplantation;113
1.6.1.2.4;5.2.4 Tumor Metastasis;114
1.6.1.2.5;5.2.5 Monitoring Tumor Progression and Determining Efficacy;115
1.6.1.2.6;5.2.6 Examples of Single Agent and Combination Preclinical Trials;117
1.6.1.3;5.3 Pros and Cons;121
1.6.1.4;5.4 Pharmacology and Pharmacokinetic Correlations;122
1.6.1.5;5.5 Future Perspectives;124
1.6.1.6;References;126
1.6.2;Chapter 6: Imaging the Steps of Metastasis at the Macro and Cellular Level with Fluorescent Proteins in Real Time;134
1.6.2.1;6.1 Introduction;134
1.6.2.2;6.2 The In Vivo Revolution Sparked by Fluorescent Proteins;135
1.6.2.2.1;6.2.1 Isolation of Stable High-Level Expression GFP and/or RFP Expressing Tumor Cell Lines;135
1.6.2.2.1.1;6.2.1.1 Production of GFP Retrovirus;135
1.6.2.2.1.2;6.2.1.2 Production of RFP Retroviral Vector;135
1.6.2.2.1.3;6.2.1.3 Production of Histone H2B-GFP Vector;136
1.6.2.2.1.4;6.2.1.4 GFP or RFP Gene Transduction of Cancer Cells;136
1.6.2.2.1.5;6.2.1.5 Establishment of Dual-Color Cancer Cells;136
1.6.2.2.2;6.2.2 Imaging Sites of Metastasis;137
1.6.2.2.2.1;6.2.2.1 Patterns of Contralateral and Regional Lung Tumor Metastases Visualized by GFP Expression in Orthotopic Models;137
1.6.2.2.2.2;6.2.2.2 GFP-Expressing Bone Metastases of Lung Cancer in Orthotopic Models;137
1.6.2.2.2.3;6.2.2.3 Prostate-Cancer Bone and Visceral Metastasis Visualized by GFP in Orthotopic Models;137
1.6.2.2.2.4;6.2.2.4 GFP-Expressing Melanoma Bone and Organ Metastasis Models;138
1.6.2.2.2.5;6.2.2.5 GFP-Expressing Brain Metastasis in Orthotopic Models;138
1.6.2.2.2.6;6.2.2.6 GFP-Expressing Experimental Multi-organ Metastases in Nude Mice;138
1.6.2.2.3;6.2.3 Whole-Body Fluorescence Optical Tumor Imaging of Tumor Growth and Metastasis;139
1.6.2.2.4;6.2.4 Whole-Body Imaging of RFP Pancreatic Cancer Progression;139
1.6.2.2.5;6.2.5 Whole-Body Imaging of RFP Prostate Cancer Progression;140
1.6.2.2.6;6.2.6 Whole-Body Imaging of GFP Colon Cancer Progression;140
1.6.2.3;6.3 Imaging Bacterial Targeting of Tumors;141
1.6.2.4;6.4 Advantages of GFP Imaging;144
1.6.2.5;6.5 Viral Labeling of Tumors with GFP in Live Animals;146
1.6.2.5.1;6.5.1 Selective In Vivo Tumor Delivery of the Retroviral Green Fluorescent Protein Gene to Report Future Occurrence of Metas;146
1.6.2.5.2;6.5.2 Telomerase-Dependent Adenovirus to Label Tumors In Vivo for Surgical Navigation;147
1.6.2.6;6.6 Color-Coded Imaging of the Tumor Microenvironment;148
1.6.2.6.1;6.6.1 Color-Coded Imaging of the Tumor–Host Interaction Using Colored Host Mice;148
1.6.2.6.1.1;6.6.1.1 Transgenic GFP Nude Mouse;148
1.6.2.6.1.2;6.6.1.2 Transgenic RFP Nude Mouse;149
1.6.2.6.1.3;6.6.1.3 Transgenic CFP Nude Mouse;150
1.6.2.6.2;6.6.2 Color-Coded Imaging in the Tumor Microenvironment;152
1.6.2.6.3;6.6.3 Noninvasive Color-Coded Imaging of the Tumor Microenvironment;152
1.6.2.7;6.7 Imaging the Cell Biology of Metastasis In Vivo;155
1.6.2.7.1;6.7.1 Dynamic Imaging of GFP or RFP-Expressing Cancer Cells in Blood Vessels and Lymphatics;155
1.6.2.7.2;6.7.2 Imaging Cancer Cell Trafficking in Blood Vessels;156
1.6.2.7.3;6.7.3 Imaging Cancer Cell Trafficking in Lymphatic Vessels;157
1.6.2.7.4;6.7.4 Determining Clonality of Metastasis Using Color-Coded Cancer Cells;158
1.6.2.8;6.8 Imaging Lateral Gene Transfer Between Cancer Cells;158
1.6.2.8.1;6.8.1 Color-Coded Imaging of Circulating Cancer Cells;158
1.6.2.8.2;6.8.2 Color-Coded Imaging of Gene Transfer Between Cancer Cells Interacting In Vivo;160
1.6.2.8.3;6.8.3 Color-Coded Imaging of Gene Transfer from High- to Low-Metastatic Osteosarcoma Cells In Vivo;160
1.6.2.9;6.9 Methods;161
1.6.2.9.1;6.9.1 Imaging Apparatus;161
1.6.2.9.1.1;6.9.1.1 In Vivo Imaging with an LED Flashlight and Filters;161
1.6.2.9.1.2;6.9.1.2 Simple Light-Box Imaging;161
1.6.2.9.1.3;6.9.1.3 In Vivo Imaging with a Fluorescence Dissecting Microscope;162
1.6.2.9.1.4;6.9.1.4 In Vivo Cellular Imaging with a Variable Magnification Imaging Chamber;162
1.6.2.9.1.5;6.9.1.5 Imaging Chambers Designed for Whole-Body Imaging;163
1.6.2.10;6.10 Patient-Like Orthotopic Tumor Models;164
1.6.2.10.1;6.10.1 Surgical Orthotopic Implantation;164
1.6.2.10.1.1;6.10.1.1 Ovarian Cancer;164
1.6.2.10.1.2;6.10.1.2 Lung Cancer;165
1.6.2.10.1.3;6.10.1.3 Prostate Cancer;165
1.6.2.10.1.4;6.10.1.4 Colon Cancer;165
1.6.2.10.1.4.1;Colonic Transplantation;165
1.6.2.10.1.4.2;Intrahepatic Transplantation;166
1.6.2.11;6.11 Technical Details;166
1.6.2.11.1;6.11.1 RFP Retrovirus Production;166
1.6.2.11.2;6.11.2 GFP Retrovirus Production;167
1.6.2.11.3;6.11.3 RFP or GFP Gene Transduction of Tumor Cell Lines;168
1.6.2.11.4;6.11.4 Cell Injection to Establish an Experimental Metastasis Model;168
1.6.2.11.5;6.11.5 Surgical Orthotopic Implantation to Establish a Spontaneous Metastasis Model;168
1.6.2.11.6;6.11.6 Imaging;169
1.6.2.11.6.1;6.11.6.1 Fluorescence Microscopy;169
1.6.2.11.6.2;6.11.6.2 Fluorescence Stereomicroscopy;169
1.6.2.11.7;6.11.7 Chamber Imaging Systems;170
1.6.2.11.7.1;6.11.7.1 Olympus OV100;170
1.6.2.11.7.2;6.11.7.2 INDEC FluorVivo;170
1.6.2.11.7.3;6.11.7.3 UVP iBox;170
1.6.2.11.8;6.11.8 Tumor Tissue Sampling;171
1.6.2.11.9;6.11.9 Measurement of GFP-expressing Tumor Blood Vessel Length and Evaluation of Antiangiogenetic Agents;171
1.6.2.11.10;6.11.10 Immunohistochemical Staining;171
1.6.2.12;References;172
1.6.3;Chapter 7: Patient-Derived Tumor Models and Explants;176
1.6.3.1;7.1 Introduction;176
1.6.3.1.1;7.1.1 Historical Perspective;176
1.6.3.1.2;7.1.2 The Strength of Human Models Derived from Patient Explants;177
1.6.3.2;7.2 Materials and Methods;178
1.6.3.2.1;7.2.1 Establishment of Human Tumor Xenografts from Patient Explants;178
1.6.3.2.1.1;7.2.1.1 Animals;180
1.6.3.2.1.2;7.2.1.2 Tumors;180
1.6.3.2.1.3;7.2.1.3 Tumor Growth Measurements;180
1.6.3.2.2;7.2.2 Experimental Design of Drug Testing;180
1.6.3.2.2.1;7.2.2.1 Study Design;180
1.6.3.2.2.2;7.2.2.2 Chemotherapy;181
1.6.3.2.2.3;7.2.2.3 Evaluation Parameters for Tumor Response;182
1.6.3.2.3;7.2.3 Molecular Target Characterization of the Freiburg Patient-Derived Tumor Xenograft Panel;182
1.6.3.2.4;7.2.4 Clonogenic Assay;183
1.6.3.2.4.1;7.2.4.1 Preparation of Single-Cell Suspensions;183
1.6.3.2.4.2;7.2.4.2 Culture Methods;183
1.6.3.2.5;7.2.5 Gene Signatures;184
1.6.3.3;7.3 Results and Discussion;185
1.6.3.3.1;7.3.1 Take Rates and Growth Behavior of Patient Tumor Explants in Nude Mice;185
1.6.3.3.2;7.3.2 Comparison of Drug Response of a Tumor Growing in the Nude Mouse and in the Patient;186
1.6.3.3.2.1;7.3.2.1 Cytotoxic Agents;186
1.6.3.3.2.2;7.3.2.2 Targeted Agents;187
1.6.3.3.3;7.3.3 Clinically Used Cytotoxic Agents Active in the Freiburg Xenograft Panel;187
1.6.3.3.3.1;7.3.3.1 Cytotoxic Drugs;187
1.6.3.3.3.2;7.3.3.2 Clinically Used Targeted Agents;188
1.6.3.3.3.3;7.3.3.3 Comparison of Freiburg Experience to Other Groups;190
1.6.3.3.4;7.3.4 Molecular Characterization of Human Tumor Xenografts for Target-Oriented Drug Discovery;191
1.6.3.3.4.1;7.3.4.1 Significance of Gene Signatures for Anticancer Therapy;191
1.6.3.3.4.2;7.3.4.2 Significance of Tumor Tissue Microarrays;192
1.6.3.3.4.3;7.3.4.3 Target Prevalence in the Freiburg Tumor Collection;193
1.6.3.3.5;7.3.5 Assessment of In Vivo Efficacy of Anticancer Agents Drug Discovery Using the Freiburg Xenograft System;194
1.6.3.3.6;7.3.6 Selected Examples of Anticancer Agents in Clinical Trials Which Have Been Discovered in a Target-Oriented Approach;197
1.6.3.3.7;7.3.7 Possible Future Impact of Patient-Derived Tumor Xenografts and Explants;198
1.6.3.4;7.4 Summary;198
1.6.3.5;References;199
1.6.4;Chapter 8: The Pediatric Preclinical Testing Program;203
1.6.4.1;8.1 Introduction;203
1.6.4.2;8.2 Selection of Preclinical Models;204
1.6.4.3;8.3 Molecular Characterization of Tumor Models;207
1.6.4.3.1;8.3.1 Model Fidelity;209
1.6.4.3.2;8.3.2 Primary Screening;210
1.6.4.3.3;8.3.3 Response Criteria: Solid Tumors;211
1.6.4.3.4;8.3.4 Response Criteria: Acute Lymphoblastic Leukemia Xenograft Models;212
1.6.4.3.4.1;8.3.4.1 Event-Free Survival;212
1.6.4.3.4.2;8.3.4.2 Tumor Growth Delay Value;213
1.6.4.3.4.3;8.3.4.3 Tumor Volume T/C Value;213
1.6.4.3.4.4;8.3.4.4 EFS T/C Value;213
1.6.4.4;8.4 Data Presentation;214
1.6.4.5;8.5 Secondary Screening;216
1.6.4.6;8.6 Combination Drug Testing;217
1.6.4.7;8.7 Secondary Models;218
1.6.4.8;8.8 Integrating Molecular Data with Drug Sensitivity;218
1.6.4.8.1;8.8.1 Submitting Agents to the PPTP;218
1.6.4.9;8.9 Closing Remarks;219
1.6.4.10;References;220
1.6.5;Chapter 9: Imaging Efficacy in Tumor Models;222
1.6.5.1;9.1 Introduction;222
1.6.5.2;9.2 Challenges in Preclinical Imaging;223
1.6.5.3;9.3 Imaging Modalities: Technical Overview and Use in Oncology Models;224
1.6.5.3.1;9.3.1 Magnetic Resonance Imaging;224
1.6.5.3.2;9.3.2 Computed Tomography;225
1.6.5.3.3;9.3.3 Positron Emission Tomography;226
1.6.5.3.4;9.3.4 Single Photon Emission Computed Tomography;227
1.6.5.3.5;9.3.5 In Vivo Optical Imaging;227
1.6.5.3.6;9.3.6 Ultrasound;228
1.6.5.4;9.4 Imaging End Points in Oncology Models;229
1.6.5.4.1;9.4.1 Anatomical Imaging;229
1.6.5.4.1.1;9.4.1.1 Tumor Detection and Staging;229
1.6.5.4.1.2;9.4.1.2 Tumor Burden;230
1.6.5.4.2;9.4.2 Functional Imaging;231
1.6.5.4.2.1;9.4.2.1 Imaging Tumor Metabolism and Metabolite Levels;231
1.6.5.4.2.2;9.4.2.2 Cell Proliferation;234
1.6.5.4.2.3;9.4.2.3 Vascular Imaging, Permeability, and Blood Flow;234
1.6.5.4.2.4;9.4.2.4 Tumor Cellularity and Cell Kill;236
1.6.5.4.2.5;9.4.2.5 Receptor Occupancy and Gene Expression;236
1.6.5.4.2.6;9.4.2.6 Tissue Hypoxia and pH;237
1.6.5.4.2.7;9.4.2.7 Apoptosis;237
1.6.5.4.2.8;9.4.2.8 Imaging of Oncogenic Pathways;238
1.6.5.4.2.9;9.4.2.9 Other Imaging Applications in Oncology;238
1.6.5.5;9.5 Imaging Efficacy in Oncology Models: Future Outlook;239
1.6.5.6;References;239
1.7;Part IV Carcinogen-Induced Tumors;249
1.7.1;Chapter 10: Mammary Cancer in Rats;250
1.7.1.1;10.1 Introduction;250
1.7.1.2;10.2 Historical Perspective;251
1.7.1.2.1;10.2.1 Induction of Mammary Carcinomas Using MNU;252
1.7.1.2.2;10.2.2 Carcinogen Dose and Age of Administration;253
1.7.1.2.3;10.2.3 Typical Animal Protocols;254
1.7.1.2.3.1;10.2.3.1 Chemoprevention Protocol;254
1.7.1.2.3.2;10.2.3.2 Therapeutic Protocol;256
1.7.1.2.4;10.2.4 Biological Characteristic of Mammary Carcinomas Induced by MNU;256
1.7.1.2.5;10.2.5 Value of this Model Relative to Genetically Engineered Models for Mammary Cancer;258
1.7.1.3;References;258
1.8;Part V Disease and Target-Specific Models;261
1.8.1;Chapter 11: Animal Models of Melanoma;262
1.8.1.1;11.1 Introduction;262
1.8.1.2;11.2 Xiphophorus Species;263
1.8.1.3;11.3 South American Opossum;264
1.8.1.4;11.4 Canine Melanoma;266
1.8.1.5;11.5 Sinclair Swine;267
1.8.1.6;11.6 Murine Models;269
1.8.1.6.1;11.6.1 Induction with Physical Agents;269
1.8.1.6.2;11.6.2 Tumors Arising in Transgenic Mice;271
1.8.1.6.3;11.6.3 Spontaneously Arising Murine Melanomas;274
1.8.1.6.3.1;11.6.3.1 Models Employing the B16 Cell Line;274
1.8.1.6.4;11.6.4 Tumor Models that Employ Immunodeficient Mice;277
1.8.1.6.4.1;11.6.4.1 Nude Mouse Models;279
1.8.1.6.4.2;11.6.4.2 SCID Mouse Models;280
1.8.1.7;References;282
1.8.2;Chapter 12: Experimental Animal Models for Investigating Renal Cell Carcinoma Pathogenesis and Preclinical Therapeutic Approac;289
1.8.2.1;12.1 Introduction;289
1.8.2.2;12.2 Murine Syngeneic Renal Adenocarcinoma: The Renca Model;290
1.8.2.3;12.3 Rat Renal Carcinoma Models;296
1.8.2.3.1;12.3.1 The Wistar–Lewis Rat Renal Adenocarcinoma;296
1.8.2.3.2;12.3.2 The Eker Rat Model;297
1.8.2.4;12.4 Xenografts of Human RCC Tumor Cell Linesin Immunodeficient Mice;298
1.8.2.5;References;302
1.8.3;Chapter 13: Animal Models of Mesothelioma;308
1.8.3.1;13.1 Introduction;308
1.8.3.2;13.2 Asbestos-Induced Mesothelioma in Animal Models;309
1.8.3.2.1;13.2.1 Types of Asbestos Fibers;309
1.8.3.2.2;13.2.2 Asbestos-Induced Animal Models of Mesothelioma: General Comments;310
1.8.3.2.3;13.2.3 Intraperitoneal Asbestos Injection;311
1.8.3.2.4;13.2.4 Intraperitoneal Asbestos Injection: Rats;311
1.8.3.2.5;13.2.5 Intraperitoneal Asbestos Injection: Mice;312
1.8.3.2.6;13.2.6 Intrapleural Asbestos Injection;313
1.8.3.2.7;13.2.7 Intrapleural Asbestos Injection: Rat;313
1.8.3.2.8;13.2.8 Inhalation of Asbestos in Animal Models;314
1.8.3.2.8.1;13.2.8.1 Inhalation Studies in Rats;314
1.8.3.2.8.2;13.2.8.2 Inhalation Studies: Guinea Pig;314
1.8.3.2.8.3;13.2.8.3 Intratracheal Asbestos Administration;314
1.8.3.2.8.4;13.2.8.4 Intratracheal Asbestos Administration: Syrian Golden Hamster;315
1.8.3.3;13.3 Spontaneous Models of Mesothelioma;315
1.8.3.4;13.4 Other Agents for Animal Production of Mesothelioma;315
1.8.3.4.1;13.4.1 Chemical;315
1.8.3.4.2;13.4.2 Man-Made Fibers;316
1.8.3.5;13.5 Novel Viral-Induced and Transgenic Knockout Models of Mesothelioma;317
1.8.3.5.1;13.5.1 SV40 Viral Hamster Models;317
1.8.3.5.2;13.5.2 SV40 Transgenic Mouse Models;319
1.8.3.5.3;13.5.3 Transgenic Murine Models, Utilizing Nf2, Ink4a/ARF, and P53 Knockout Mice;319
1.8.3.6;13.6 Orthotopic Transplants and Xenograft;320
1.8.3.7;13.7 Conclusions;322
1.8.3.8;References;322
1.8.4;Chapter 14: The Use of Mouse Models to Study Leukemia/Lymphoma and Assess Therapeutic Approaches;326
1.8.4.1;14.1 Introduction;326
1.8.4.1.1;14.1.1 Models of Myeloid Leukemia;328
1.8.4.1.2;14.1.2 Models of Acute Lymphocytic Leukemia;331
1.8.4.1.3;14.1.3 Chronic Lymphocytic Leukemia;333
1.8.4.1.4;14.1.4 HTLV-Related T Cell Leukemia/Lymphoma;335
1.8.4.2;14.2 Models of Hodgkin’s Lymphoma;335
1.8.4.3;14.3 Models of Non-Hodgkin’s Lymphoma;337
1.8.4.4;14.4 Models of Multiple Myeloma;340
1.8.4.5;14.5 Conclusions;342
1.8.4.6;References;343
1.8.5;Chapter 15: Spontaneous Companion Animal (Pet) Cancers;353
1.8.5.1;15.1 Introduction;353
1.8.5.2;15.2 Overview of Cancer in Companion Animal Species;354
1.8.5.2.1;15.2.1 Cancer Incidence and Availability of Veterinary Medical Care;354
1.8.5.2.2;15.2.2 Genetic and Molecular Basis of Cancer in Pet Dogs;355
1.8.5.3;15.3 Potential Opportunities/Advantages of Including Companion Animals with Cancer as Models;358
1.8.5.4;15.4 Caveats to Inclusion of Pet Dogs with Cancer as Models;362
1.8.5.5;15.5 The Vested Communities;364
1.8.5.6;15.6 Study Design Issues Specific to Companion Species Trials;366
1.8.5.7;15.7 Conclusions;368
1.8.5.8;References;369
1.9;Part VI Genetically Engineered Mouse Models of Cancer;374
1.9.1;Chapter 16: Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma;375
1.9.1.1;16.1 Pancreas Anatomy, Physiology, and Development;376
1.9.1.2;16.2 Histological and Molecular Characteristics of Human PDAC;377
1.9.1.3;16.3 Modeling PDAC;378
1.9.1.4;16.4 Transgenic Expression of Oncogenes in the Pancreas;379
1.9.1.5;16.5 Viral Delivery of Oncogenes;380
1.9.1.6;16.6 Compound Inducible Mutants;380
1.9.1.6.1;16.6.1 Cooperation Between Kras and Tumor Suppressors in PDAC;382
1.9.1.6.2;16.6.2 Preclinical Studies;384
1.9.1.7;16.7 Ongoing and Future Modeling Efforts;386
1.9.1.8;16.8 Conclusions;388
1.9.1.9;References;388
1.9.2;Chapter 17: Transgenic Adenocarcinoma of the Mouse Prostate: A Validated Model for the Identification and Characterization of M;394
1.9.2.1;17.1 Introduction;394
1.9.2.2;17.2 Generation of the TRAMP Model and Phenotypic Characterization;396
1.9.2.3;17.3 Gene Expression Profiling Studies;398
1.9.2.4;17.4 Epigenetic Regulation of Gene Expression;400
1.9.2.5;17.5 Validating and Elucidating Gene Function Through Additional Genetic Engineering;403
1.9.2.6;17.6 Testing of Known and Putative Therapeutic Agents;404
1.9.2.7;17.7 Summary, Conclusions, and Future Directions;411
1.9.2.8;References;412
1.9.3;Chapter 18: The Utility of Transgenic Mouse Models for Cancer Prevention Research;419
1.9.3.1;18.1 Introduction;419
1.9.3.2;18.2 Cancer Prevention in Transgenic Mice: Lessons Learned from Commonly Used Models;420
1.9.3.2.1;18.2.1 Mutant Mouse Models for Prostate Cancer Prevention;420
1.9.3.2.1.1;18.2.1.1 PTEN Mutant Mouse Models;420
1.9.3.2.1.2;18.2.1.2 c-Myc Transgenic Mice;421
1.9.3.2.1.3;18.2.1.3 Viral Oncogene Models;421
1.9.3.2.2;18.2.2 Mutant Mouse Models for Mammary Cancer Prevention;423
1.9.3.2.2.1;18.2.2.1 TGFa Models;423
1.9.3.2.2.2;18.2.2.2 ErbB-2/HER2/neu Models;423
1.9.3.2.2.3;18.2.2.3 SV40 T-antigen Transgenic Models;424
1.9.3.2.2.4;18.2.2.4 p53-mutant Mouse Models;424
1.9.3.2.2.5;18.2.2.5 MMTV-Wnt-1 Transgenic Mouse Model;425
1.9.3.2.2.6;18.2.2.6 Ras Mutant Models;426
1.9.3.2.2.7;18.2.2.7 c-myc Transgenic Mice;426
1.9.3.2.2.8;18.2.2.8 Cyclin D1 Transgenic Mice;426
1.9.3.2.2.9;18.2.2.9 Inducible Models;427
1.9.3.2.2.10;18.2.2.10 Examples of Dietary or Chemopreventive Studies Using Transgenic Mouse Models of Mammary Cancer;427
1.9.3.2.2.10.1;Selective Estrogen Receptor Modulators;427
1.9.3.2.2.10.2;Aromatase Inhibitors;428
1.9.3.2.2.10.3;Retinoids;428
1.9.3.2.2.10.4;Tyrosine Kinase Inhibitors;428
1.9.3.2.2.10.5;Nonsteroidal Anti-Inflammatory Drugs/Cyclooxygenase-2 Inhibitors;429
1.9.3.2.2.10.6;Energy Balance Interventions;429
1.9.3.2.3;18.2.3 Apc-Deficient Models for Intestinal Cancer Prevention Studies;429
1.9.3.2.4;18.2.4 Emerging Models of Pancreatic Cancer;430
1.9.3.3;18.3 Summary and Conclusions;432
1.9.3.4;References;433
1.10;Part VII Metastasis Models;440
1.10.1;Chapter 19: Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease;441
1.10.1.1;19.1 Introduction;441
1.10.1.2;19.2 Therapeutic Strategies for Targeting Metastases;443
1.10.1.2.1;19.2.1 Target Identification and Validation;443
1.10.1.2.2;19.2.2 Molecular Targets;444
1.10.1.2.2.1;19.2.2.1 Oncogenic Receptor Tyrosine Kinase Signaling Pathways;444
1.10.1.2.2.2;19.2.2.2 HSP90 Chaperone;456
1.10.1.2.2.3;19.2.2.3 Chemokine Receptors;456
1.10.1.2.2.4;19.2.2.4 BCr-Abl: A Paradigm for Tumor-Specific Therapy;457
1.10.1.2.2.5;19.2.2.5 Hedgehog (Hh);457
1.10.1.2.2.6;19.2.2.6 Wnt Pathway;458
1.10.1.2.2.7;19.2.2.7 Combination Therapies;458
1.10.1.2.3;19.2.3 Processes Linked to Metastasis;458
1.10.1.2.3.1;19.2.3.1 Angiogenesis and Hypoxia;458
1.10.1.2.3.2;19.2.3.2 Proteolysis in Invasion and Angiogenesis;460
1.10.1.2.3.3;19.2.3.3 Intravasation and Extravasation;460
1.10.1.2.3.4;19.2.3.4 The Premetastatic Niche;461
1.10.1.2.4;19.2.4 Resistance to Therapy;461
1.10.1.2.4.1;19.2.4.1 Cancer Stem-Like Cells;461
1.10.1.2.4.2;19.2.4.2 Dormant Metastases;462
1.10.1.2.5;19.2.5 Immunological Approaches;463
1.10.1.2.5.1;19.2.5.1 Antibody-Based Therapies;463
1.10.1.2.5.2;19.2.5.2 Vaccines, Cytokines, and Cell-Mediated Immunotherapy;463
1.10.1.2.5.3;19.2.5.3 Targeting Using Vectors or Peptides with Tumor Selectivity;464
1.10.1.3;19.3 Detection and Quantitation of Metastases and Determination of Therapeutic Benefit;464
1.10.1.4;19.4 Animal Models for Evaluating Targeted Therapy of Metastasis;466
1.10.1.4.1;19.4.1 Syngeneic Rodent Tumor Models;466
1.10.1.4.2;19.4.2 Human Tumor Xenograft Models;466
1.10.1.4.3;19.4.3 Organ Colonization and Site-Selective Metastases;468
1.10.1.4.3.1;19.4.3.1 Lung Metastases;468
1.10.1.4.3.2;19.4.3.2 Liver Metastasis;469
1.10.1.4.3.3;19.4.3.3 Brain Metastasis;469
1.10.1.4.3.4;19.4.3.4 Bone Metastasis;469
1.10.1.4.4;19.4.4 Spontaneous Metastasis Models;470
1.10.1.4.4.1;19.4.4.1 Orthotopic Implantation Models;471
1.10.1.4.4.2;19.4.4.2 Lymph Node Metastases;471
1.10.1.4.5;19.4.5 Transgenic Models;472
1.10.1.5;19.5 Summary and Conclusions;474
1.10.1.6;References;475
1.11;Part VIII Normal Tissue Response Models;490
1.11.1;Chapter 20: Animal Models of Toxicities Caused by Anti-Neoplastic Therapy;491
1.11.1.1;20.1 Introduction;491
1.11.1.2;20.2 Models of Oral Mucositis Induced by Anti-Neoplastic Drugs and Radiation;492
1.11.1.2.1;20.2.1 Overview of the Condition;492
1.11.1.2.2;20.2.2 The Biology of Mucositis;493
1.11.1.2.3;20.2.3 Objectives of Animal Models of Mucositis;494
1.11.1.2.4;20.2.4 Current Models;494
1.11.1.2.4.1;20.2.4.1 Screening Models for the Enablement of Pharmaceuticalsand Biologicals;496
1.11.1.2.4.1.1;Background;496
1.11.1.2.4.1.2;History of Radiation Model Development in Hamsters;496
1.11.1.2.4.2;20.2.4.2 The Hamster Model for Acute Radiation-Induced Mucositis;496
1.11.1.2.4.3;20.2.4.3 Non-Clinical Endpoints;1
1.11.1.2.4.4;20.2.4.4 The Hamster Model for Fractionated Radiation-Induced Mucositis;500
1.11.1.2.4.5;20.2.4.5 Hamster Models for Chemotherapy-Induced Mucositis Withor Without Concomitant Radiation;500
1.11.1.2.4.6;20.2.4.6 Chemotherapy-Induced Oral Mucositis;500
1.11.1.2.4.7;20.2.4.7 Concomitant Chemotherapy and Radiation;501
1.11.1.3;20.3 Chemotherapy-Induced Mucositis of the GI Tract;501
1.11.1.3.1;20.3.1 Models of Intestinal Mucositis;501
1.11.1.3.1.1;20.3.1.1 Use of Endoscopy to Assess Chemotherapy-Induced Mucosal Injury;502
1.11.1.4;20.4 Radiation-Induced Proctitis;503
1.11.1.4.1;20.4.1 Overview of the Condition;503
1.11.1.4.2;20.4.2 The Biology of Radiation-Induced Proctitis;503
1.11.1.4.3;20.4.3 Animal Model of Radiation-Induced Proctitis;504
1.11.1.4.3.1;20.4.3.1 Radiation-Induced Dermatitis;504
1.11.1.4.3.1.1;Overview of the Condition;504
1.11.1.4.4;20.4.4 The Biology of Radiation-Induced Dermatitis;505
1.11.1.4.5;20.4.5 Animal Model of Radiation-Induced Dermatitis;505
1.11.1.4.6;20.4.6 Bisphosphonate-Related Osteonecrosis of the Jaws;507
1.11.1.4.6.1;20.4.6.1 Introduction;507
1.11.1.4.6.2;20.4.6.2 Rat Model for Bisphosphonate-Associated Osteonecrosis of the Jaws;508
1.11.1.5;References;509
1.11.2;Chapter 21: Bone Marrow as a Critical Normal Tissuethat Limits Drug Dose/Exposure in Preclinical Models and the Clinic1;512
1.11.2.1;21.1 Introduction;513
1.11.2.2;21.2 Blood Cytopenia as a Quantifiable Dose-Limiting Toxicity in the Oncology Clinic;514
1.11.2.3;21.3 Cancer Therapeutics as Toxicants to Highly Proliferative Hematopoietic Cells;516
1.11.2.4;21.4 Bone Marrow as a Critical Normal Tissue that Sets Maximum Human Dose/Exposure and Therefore Should Restrict Dose/Exposur;521
1.11.2.5;21.5 Using Hematotoxicology to Limit Treatment of Mouse Models to Tolerated Human Doses/Exposures;523
1.11.2.5.1;21.5.1 Method 1: Treating Mouse Models at Maximum Tolerated Human Dose, Predicted Using CFU-GM Assays;524
1.11.2.5.2;21.5.2 Method 2: Treating Mouse Models at Maximum Tolerated Human Dose/Exposure Determined Empirically Using NOD/SCID Mice En;528
1.11.2.6;21.6 Concluding Thoughts on Improving the Predictive Accuracy of Mouse Efficacy Models Using Human Hematotoxicology Data;536
1.11.2.7;References;538
1.11.3;Chapter 22: Anesthetic Considerations for the Study of Murine Tumor Models;544
1.11.3.1;22.1 Overview;544
1.11.3.2;22.2 Rationale and Requirements for Animal Anesthesia in Cancer Research;544
1.11.3.2.1;22.2.1 Humane Reasons;545
1.11.3.2.2;22.2.2 To Control Motion;545
1.11.3.3;22.3 Special Requirements for Anesthesia in Cancer Research;545
1.11.3.3.1;22.3.1 Non-Survival Surgery;545
1.11.3.3.2;22.3.2 Survival Surgery;545
1.11.3.3.3;22.3.3 Functional Studies;546
1.11.3.3.4;22.3.4 Controlled Delivery of Anticancer Treatment;546
1.11.3.3.5;22.3.5 Assessment of Anesthetic Depth in Rodents;547
1.11.3.4;22.4 Animal Support;547
1.11.3.4.1;22.4.1 Body Temperature;547
1.11.3.4.2;22.4.2 Respiration;548
1.11.3.4.3;22.4.3 Hydration;549
1.11.3.4.4;22.4.4 Analgesia;549
1.11.3.4.5;22.4.5 Inhalable Anesthetics;549
1.11.3.5;22.5 Isoflurane;550
1.11.3.5.1;22.5.1 Background About the Drug;550
1.11.3.5.2;22.5.2 Anesthetic Properties;551
1.11.3.5.3;22.5.3 Typical Applications;551
1.11.3.5.4;22.5.4 Required Equipment;552
1.11.3.5.5;22.5.5 Protocol for Isoflurane in Mice and Rats;552
1.11.3.5.6;22.5.6 Induction of Anesthesia in Rats with Isoflurane, Followed by Injectable Anesthesia;552
1.11.3.6;22.6 Injectible Anesthetics;553
1.11.3.6.1;22.6.1 Ketamine HCl with Xylazine;553
1.11.3.6.1.1;22.6.1.1 Background and Biochemistry;553
1.11.3.6.1.2;22.6.1.2 Anesthetic Properties in Rodents;553
1.11.3.6.1.3;22.6.1.3 Impact of Ketamine on Rodent Physiology;554
1.11.3.6.1.4;22.6.1.4 Anesthesia Protocol of Mice Using Ketamine/Xylazine Anesthesia;554
1.11.3.6.1.4.1;Preparation;554
1.11.3.6.1.4.2;Protocol;554
1.11.3.7;22.7 Pentobarbital;555
1.11.3.7.1;22.7.1 Background and Biochemistry;555
1.11.3.7.2;22.7.2 Anesthetic Properties in Rodents;555
1.11.3.7.3;22.7.3 Physiological Impact of Pentobarbital;556
1.11.3.7.4;22.7.4 Applications;556
1.11.3.7.5;22.7.5 Protocol for Pentobarbital Anesthesia in Mice;556
1.11.3.7.5.1;22.7.5.1 Preparation;556
1.11.3.7.5.2;22.7.5.2 Protocol;557
1.11.3.7.6;22.7.6 Other Injectibles;557
1.11.3.8;22.8 Summary;557
1.11.3.9;References;558
1.12;Part IX Experimental Methods and Endpoints;560
1.12.1.1;23.1 Introduction;1
1.12.1.2;23.2 Ascites Tumors;562
1.12.1.3;23.3 Solid Tumors;564
1.12.1.4;23.4 Combination Treatments;568
1.12.1.5;23.5 Therapeutic Index;576
1.12.1.6;23.6 In Vivo/Ex Vivo Assay of Primary and Metastatic Disease;577
1.12.1.7;23.7 In Vivo Resistant Tumors;579
1.12.1.8;23.8 Drug Penetration into Tumor;580
1.12.1.9;23.9 Conclusion;587
1.12.1.10;References;588
1.12.2;Chapter 24: Tumor Cell Survival;596
1.12.2.1;24.1 Introduction;597
1.12.2.2;24.2 Selection of Tumor–Host Systems;598
1.12.2.3;24.3 Cell Survival Assays;600
1.12.2.3.1;24.3.1 Implications of Clonogenic Cell Survival;600
1.12.2.3.2;24.3.2 Measuring Clonogenicity;600
1.12.2.3.2.1;24.3.2.1 Identifying Clonogenic Cells;601
1.12.2.3.2.2;24.3.2.2 Motion Artifacts;603
1.12.2.3.2.3;24.3.2.3 Cell Density Problems;603
1.12.2.3.2.4;24.3.2.4 Colony Density Problems;604
1.12.2.3.2.5;24.3.2.5 Counting the Colonies;604
1.12.2.3.3;24.3.3 Tumor Cell Suspensions;605
1.12.2.3.3.1;24.3.3.1 Preparing the Suspension;605
1.12.2.3.3.2;24.3.3.2 Counting the Cells;606
1.12.2.3.3.3;24.3.3.3 The Importance of Single-Cell Suspensions;606
1.12.2.3.4;24.3.4 Scheduling Problems in Clonogenic Assays;607
1.12.2.4;24.4 Analysis of Cell Survival Data;609
1.12.2.5;24.5 Conclusions;611
1.12.2.6;References;611
1.12.3;Chapter 25: Apoptosis In Vivo;614
1.12.3.1;25.1 Introduction;614
1.12.3.2;25.2 Recognition and Quantification of Apoptosis;615
1.12.3.2.1;25.2.1 Morphological Assessment In Vivo;615
1.12.3.2.2;25.2.2 Quantification of Apoptosis In Vitro;616
1.12.3.3;25.3 Apoptosis in Tumor Biology;617
1.12.3.3.1;25.3.1 The Role of Apoptosis in Tumor Development;617
1.12.3.3.2;25.3.2 Genetic Regulation of Apoptosis;618
1.12.3.4;25.4 Apoptosis in Cancer Therapy;620
1.12.3.4.1;25.4.1 Response of Normal Tissue to Cytotoxic Therapy;620
1.12.3.4.2;25.4.2 Apoptosis in Tumors Responding to Cytotoxic Therapy;621
1.12.3.4.3;25.4.3 In Vivo Imaging of Apoptosis;624
1.12.3.5;25.5 Summary and Conclusions;625
1.12.3.6;References;625
1.12.4;Chapter 26: Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function and Therapeuti;630
1.12.4.1;26.1 Introduction;630
1.12.4.2;26.2 Chronic Window Preparations;633
1.12.4.2.1;26.2.1 Procedures;635
1.12.4.2.1.1;26.2.1.1 Rabbit Ear Chamber;635
1.12.4.2.1.2;26.2.1.2 Dorsal Skin Chamber Preparation;636
1.12.4.2.1.3;26.2.1.3 Mammary Fat Pad Chamber Preparation;637
1.12.4.2.1.4;26.2.1.4 Cranial Window Preparation;637
1.12.4.2.1.5;26.2.1.5 Angiogenesis Gel Assay and Tissue Engineered Vessel Model;638
1.12.4.3;26.3 Acute (Exteriorized) Preparations;641
1.12.4.3.1;26.3.1 Procedures;641
1.12.4.3.1.1;26.3.1.1 Mesentery;641
1.12.4.3.1.2;26.3.1.2 Liver Tumor Preparation;641
1.12.4.3.1.3;26.3.1.3 Pancreatic Tumor Preparation;642
1.12.4.3.1.4;26.3.1.4 Mammary Fat Pad Tumor Preparation;643
1.12.4.4;26.4 In Situ Preparations;643
1.12.4.4.1;26.4.1 Procedures;644
1.12.4.4.1.1;26.4.1.1 Corneal Pocket Assay;644
1.12.4.4.1.2;26.4.1.2 Chick Chorioallantoic Membrane;644
1.12.4.4.1.3;26.4.1.3 Tail Lymphatics;645
1.12.4.4.1.4;26.4.1.4 Ear Model;645
1.12.4.5;26.5 Intravital Microscopy and Image Analysis;647
1.12.4.5.1;26.5.1 Intravital Microscopy Work Station;647
1.12.4.5.1.1;26.5.1.1 Conventional Single-Photon Microscopy;647
1.12.4.5.1.2;26.5.1.2 Multiphoton Laser-Scanning Microscopy;647
1.12.4.5.1.3;26.5.1.3 Optical Frequency Domain Imaging;647
1.12.4.5.2;26.5.2 Tumor Growth and Regression;649
1.12.4.5.3;26.5.3 Vascular Parameters;649
1.12.4.5.3.1;26.5.3.1 Angiogenesis and Hemodynamics;649
1.12.4.5.3.1.1;Single-Photon Microscopy Procedure;650
1.12.4.5.3.1.2;Multiphoton Laser-Scanning Microscopy Procedure;650
1.12.4.5.3.2;26.5.3.2 Vascular Permeability;651
1.12.4.5.3.2.1;Single-Photon Microscopy Procedure;651
1.12.4.5.3.2.2;Multiphoton Laser-Scanning Microscopy Procedure;651
1.12.4.5.3.3;26.5.3.3 Leukocyte Endothelial Interactions;652
1.12.4.5.3.3.1;Single-Photon Microscopy Procedure [92];652
1.12.4.5.3.3.2;Multiphoton Laser-Scanning Microscopy Procedure [80];652
1.12.4.5.4;26.5.4 Extravascular Parameters;653
1.12.4.5.4.1;26.5.4.1 Interstitial pH Measurements;653
1.12.4.5.4.2;26.5.4.2 Interstitial and Microvascular pO2 Measurements;654
1.12.4.5.4.3;26.5.4.3 Tissue Nitric Oxide Distribution;654
1.12.4.5.4.4;26.5.4.4 Interstitial Diffusion, Convection, and Bindings;655
1.12.4.5.4.4.1;Single-Photon Fluorescence Recovery After Photobleaching Procedures;655
1.12.4.5.4.4.2;Multiphoton Fluorescence Recovery After Photobleaching Procedures [101];656
1.12.4.5.4.4.3;Multiphoton Fluorescence Correlation Spectroscopy Procedures [102];656
1.12.4.5.4.5;26.5.4.5 Gene Expression: Promoter Activity via GFP Imaging;657
1.12.4.6;26.6 Novel Insights;658
1.12.4.7;26.7 Future Perspectives;660
1.12.4.8;References;660
1.13;Index;669




